Ipamorelin vs GHRP-2: Potency and Selectivity
TL;DR · The short version
Ipamorelin vs GHRP-2 includes separate comparisons of potency, maximum GH response and hormone selectivity. The original swine experiment found different GH and ACTH/cortisol profiles. Keep that model in the conclusion; it doesn’t establish a universal winner or human safety standard.
“More potent” identifies a measurement. It doesn’t finish the comparison.
The original work lets us ask how much stimulus was needed, how large the response became and which other hormones changed. Read those separately instead of reducing the compounds to strong and gentle labels.
What does the original ipamorelin comparison show?
Quick take: Read the GH finding and the other hormone findings together.
Raun and colleagues’ 1998 study examined ipamorelin, a synthetic pentapeptide, in cell and animal experiments, including a comparison with GHRP-2 in conscious swine.
GHRP-2 required less stimulus for its GH response, but ipamorelin reached a higher maximum GH response in that experiment. The hormone panel also mattered: GHRP-2 increased ACTH and cortisol, whereas the ipamorelin results were not statistically different from the GHRH comparison for those endpoints.
Selectivity here describes the measured hormone profile and comparators. It doesn’t guarantee absence of every other effect.
Ipamorelin vs GHRP-2: potency, maximum response and selectivity
Quick take: These terms describe different parts of a comparison.
| Question | Term to look for | What to record |
|---|---|---|
| How much stimulus produces a defined response? | Potency | The response criterion, units and concentration or exposure range. |
| How large is the response within the experiment? | Maximum response | The measured endpoint, reference response and observation window. |
| Which other measured responses change? | Selectivity | The full endpoint panel, comparison group and statistical result. |
Two hypothetical curves can differ in both concentration and maximum. One reaches a response with less stimulus but plateaus lower; the other reaches a higher maximum with more stimulus. A single strength score would lose the distinction.
GH response doesn’t describe ACTH or cortisol. Comparing selectivity needs those hormone measurements in the relevant experimental context too.
“Not statistically different” reports the analysis performed. It isn’t an exactly zero response or proof that all other endpoints were unchanged.
Why the biological model belongs in the answer
Quick take: Carry the species and preparation into your notes, not just the peptide names.
Keep selective attached to the swine comparison as the finding moves into a table or summary. Turning it into a general human profile changes what the experiment established.
Research on related secretagogues illustrates the importance of the model. Wu and colleagues compared GHRP-2 and GHRP-6 in ovine and rat pituitary cultures. GHRP-2’s cAMP response differed between the species. That paper isn’t an ipamorelin head-to-head trial; it is a useful example of why a signaling result shouldn’t be transferred automatically between experimental systems.
When reading an ipamorelin versus GHRP-2 comparison, check whether both compounds were actually included. Then look at the preparation, sampling window and measured hormones. A result from a culture, an intact animal or a human study needs its own description.
What about appetite and side-effect comparisons?
Quick take: Look for a direct comparison before accepting a ranking.
A small controlled study of GHRP-2 and food intake included seven healthy lean men and a saline comparison. Food intake increased with GHRP-2. Ipamorelin wasn’t a study arm, so this finding cannot tell us which of the two produces a greater appetite response.
Hormone-panel evidence concerns the hormones measured. A broader safety comparison needs suitable outcomes and populations. “Fewer side effects” can’t replace that study design.
A practical way to review the material and the paper
Quick take: Verify the sample separately from the biological claim.
Keep two records before drafting a brief: the study’s compound, model, endpoint and comparator, and the supplied material’s identity, amount basis, lot and analyses. That separation prevents one from certifying the other.
For example, a hypothetical brief might say “swine GH and ACTH/cortisol comparison” in the evidence note. It should not turn into “confirmed human selectivity” in the material note. A vial’s documentation doesn’t change the population in the paper.
Our purity versus identity guide explains why a high chromatographic percentage isn’t a complete identity statement. Use the public peptide COA results library to inspect lot-specific reports and match the tested lot to your material. If the methods are unfamiliar, the HPLC, LC-MS and NMR overview separates their roles.
Common comparison questions
Quick take: Ask which result a label is describing.
Are ipamorelin and GHRP-2 interchangeable?
A shared GH-release research context doesn’t make two compounds the same experimental variable. Keep their identities and response data separate, and use the exact comparator reported in the study.
Does greater potency mean a greater maximum GH response?
No. Potency concerns the stimulus required for a defined response. Maximum response concerns the size of the response within the tested system. Neither term should replace the other in a comparison table.
Does selective mean side-effect free?
No. Selectivity describes a defined response profile. Identify its measurements, model and comparator before extending the term.
This article interprets published research. It does not provide dosing instructions or recommend human or veterinary use.